Form 4: Blueprint Medicines CEO Kate Haviland Sells Shares Under 10b5-1 Trading Plan

Blueprint Medicines CEO Kate Haviland sold 1,446 shares of common stock at $110.24 per share on January 21, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Kate Haviland, CEO of Blueprint Medicines, sold 1,446 shares of common stock on January 21, 2025.
• The sale was executed at a price of $110.24 per share.
• This transaction was conducted under a pre-arranged trading plan adopted on August 30, 2024, in accordance with Rule 10b5-1.
• Following the transaction, Ms. Haviland directly owns 149,378 shares of Blueprint Medicines common stock.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by the CEO under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

Executive stock sales are a common occurrence and are often part of pre-arranged trading plans to avoid accusations of insider trading. This transaction is not unusual for a company of this size and stage.

Comparison to Industry Standards

• Executive stock sales are a common practice across the biotechnology industry.
• Many executives use 10b5-1 trading plans to manage their personal finances and avoid potential conflicts of interest.
• The volume of shares sold is relatively small compared to the total outstanding shares of Blueprint Medicines.

Stakeholder Impact

• The stock sale is unlikely to have a significant impact on shareholders, as it was a small transaction under a pre-arranged plan.

Key Dates

Keywords

Blueprint Medicines, Kate Haviland, stock sale, 10b5-1 trading plan, executive stock transaction, BPMC